CN104046630A - Aptamer having specificity with human cytomegalovirus PP65 antigen - Google Patents

Aptamer having specificity with human cytomegalovirus PP65 antigen Download PDF

Info

Publication number
CN104046630A
CN104046630A CN201310549433.8A CN201310549433A CN104046630A CN 104046630 A CN104046630 A CN 104046630A CN 201310549433 A CN201310549433 A CN 201310549433A CN 104046630 A CN104046630 A CN 104046630A
Authority
CN
China
Prior art keywords
seq
aptamer
antigen
library
specificity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201310549433.8A
Other languages
Chinese (zh)
Other versions
CN104046630B (en
Inventor
张波
夏宇
王永虎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Third Military Medical University TMMU
First Affiliated Hospital of TMMU
Original Assignee
First Affiliated Hospital of TMMU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by First Affiliated Hospital of TMMU filed Critical First Affiliated Hospital of TMMU
Priority to CN201310549433.8A priority Critical patent/CN104046630B/en
Publication of CN104046630A publication Critical patent/CN104046630A/en
Application granted granted Critical
Publication of CN104046630B publication Critical patent/CN104046630B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention discloses an aptamer having specificity with a human cytomegalovirus PP65 antigen. The gene sequence of the aptamer is represented by SEQ ID No: 1, or SEQ ID No: 2, or SEQ ID No: 3, or SEQ ID No: 4, or SEQ ID No: 5, or SEQ ID No: 6. The oligonucleotide aptamer specifically combined with PP65 is screened from a random ssNDA library by using a systematic evolution technology of ligand by exponential enrichment with the PP65 protein as a target molecule, and the structure of the screened aptamer is analyzed. Compared with antibodies in traditional detection technologies, the oligonucleotide aptamer has the advantages of strong bonding power with the target molecule, good stability, high accuracy, good repeatability, repeated use, long term preservation, accurate site modification, short screening period and the like.

Description

A kind of have specific aptamer with human cytomegalic inclusion disease virus PP65 antigen
Technical field
The invention belongs to biomedical sector, specifically, relate to a kind of and human cytomegalic inclusion disease virus PP65 antigen and there is specific aptamer.
Background technology
Human cytomegalic inclusion disease virus (human cytomegalovirus, HCMV) belongs to herpetoviridae second group bleb subfamily, is a kind of duplex DNA virus.HCMV is worldwide distribution, wide-scale distribution in crowd, and virus is hidden for a long time in host cell, is inapparent infection.Work as gestation, easily cause fetal in utero to infect, cause miscarriage, premature labor, stillborn foetus or fetus congenital malformation; Work as bone marrow transplantation, during the Organ Transplantation Patients immune function depressions such as liver, kidney, heart, latent virus is activated, rises in value and severe infections occurs, and will cause patient's organ transplantation failure even dead.In recent years, there are some researches show that cytomegalovirus infection and some diseases associated with inflammation and proliferative disease have close relationship, comprise some cardiovascular disorder and cancer.Now, cytomegalovirus infection causes great threat to human health, therefore the early diagnosis that HCMV is infected seems particularly important.In HCMV experiment detection technique, viral separation is the gold standard detecting, but length consuming time, result is affected greatly by the sample shelf time.Antibody test need just can detect after patient infection's certain hour, affected by patient's autoimmune state larger, and can not distinguish latent infection and Active infection.Antigenemia detection technique is quick, a responsive diagnostic techniques, but traditional detection method is virus antigen detection carrier mainly with white corpuscle, has limited its clinical application.And its sensitivity and specificity of diagnostic nucleic acid is all good, but testing cost is high and method for extracting nucleic acid need to improve.
SELEX technology, Fas lignand system evolution (the Systematic evolution of ligands byexponential enrichment that claims again exponential enrichment, SELEX) technology is a kind of new combinatorial chemistry technique, apply jumbo random oligonucleotide, and in conjunction with PCR Amplification Technologies, with the oligonucleotide of exponential enrichment and target molecule specific combination, through several screening processes of taking turns or counting wheel, obtain the aptamer of high-affinity, high specific.In the molecular recognition field of laboratory diagnosis and clinical treatment, it provides a technique means quicker, sensitiveer than antibody.At present, this technology has been successfully applied to the screening of many target materials, comprises albumen, small molecules, metal ion, some complicated targets such as virus, bacterium, cell even, and part nucleic acid aptamer has entered clinical experimental stage.
Summary of the invention
The object of the invention is to overcome the deficiencies in the prior art, provide a kind of and there is specific aptamer with human cytomegalic inclusion disease virus PP65 antigen.
The technical scheme that the present invention realizes object is:
There is a specific aptamer with human cytomegalic inclusion disease virus PP65 antigen, it is characterized in that: it has one of sequence of SEQ ID No.1~SEQ ID No.6.
The secondary conformation of SEQ ID No.1~SEQ ID No.6 respectively is:
Beneficial effect: the present invention compares with the antibody in traditional detection technology, oligonucleotide aptamer also stronger, the good stability of tool and target molecule bonding force, accuracy high, reproducible, can Reusability, can preserve for a long time, can carry out the advantages such as the modification of accurate site, screening be shorter.
Accompanying drawing explanation
Fig. 1 is the affinity distribution plan of inventor cytomegalovirus PP65 antigen aptamer and target material.
Embodiment
Below, by the concrete operation step of human cytomegalic inclusion disease virus PP65 antigen aptamer screening, the invention will be further described.
Embodiment mono-, structure random single chain DNA (ssDNA) library and primer
Building length is the ssDNA library of 78 bases, and two ends are fixed sequence program, and middle 35 Nucleotide are stochastic sequence, and wherein N represents A, T, and C, any one in G, storage capacity is about 10 15-10 16: 5 '-GGGAGCTCAGAATAAACGCTCAA-N35-TTCGACATGAGGCCCGGATC-3 '.Upstream primer is 5 '-GGGAGCTCAGAATAAACGCTCAA-3 ', and downstream primer is 5 '-biotin-(CH2)-TTCGACATGAGGCCCGGATC-3 '.Random single-stranded DNA banks and primer Ke You primer Synesis Company are synthetic.
Pcr amplification and the recovery in double-stranded DNA (dsDNA) library:
PCR reaction system
Reaction parameter Add-on (unit: μ l)
10*PCR damping fluid 2.0
MgCl2(25mmol/L) 1.2
dNTP(2.5mmol/L) 1.6
Primer 1 (10pmol/L) 1.0
Primer 2 (10pmol/L) 1.0
Template (ssDNA library) 0.1
TaqDNA polysaccharase 1.0
ddH2O 12.1
Cumulative volume 20.0
PCR reaction conditions
Temperature (℃) Effect Time (S)
94 Denaturation 300
94 Sex change 30
65 Annealing 30
72 Extend 30
Carry out altogether 18 circulations, last 72 ℃ are extended 5min., the product obtaining carries out next step experiment (or 4 ℃ of preservations) PcR product purification and recovery: toward the sodium acetate of 3mol/LpH5.2 and the ice-cold dehydrated alcohol of 2-2.5 times of volume that add 0.1 times of volume in DNA solution, on spiral mixer oscillator, vibration mixes and is placed in-20 ℃ of refrigerators and places 30min, then the centrifugal 5min of 12000rpm, abandon supernatant, 70% ethanol that adds 1ml precooling, put upside down centrifuge tube for several times, the centrifugal 5min of 12000rpm, abandon supernatant, after drying precipitation, (can be placed in baking oven 10min) is dissolved in 20 μ LTE damping fluid (pH8.0) or ddH2O, 4 ℃ of preservations are spent the night.
Pcr amplification and the recovery in single stranded DNA (dsDNA) library:
Adopt asymmetric PCR to increase,
PCR reaction system
Reaction parameter Add-on (unit: μ l)
10*PCR damping fluid 2.0
MgCl2(25mmol/L) 0.2
dNTP(2.5mmol/L) 1.6
Primer 1 (0.4pmol/L) 0.5
Primer 2 (10pmol/L) 2.0
Template (dsDNA library) 0.5
TaqDNA polysaccharase 0.4
ddH2O 12.8
Cumulative volume 20.0
PCR reaction conditions
Temperature (℃) Effect Time (S)
94 Denaturation 300
94 Sex change 30
65 Annealing 30
72 Extend 45
Carry out altogether 40 circulations, last 72 ℃ are extended 7min., and the product obtaining carries out the recovery in next step experiment (or 4 ℃ of preservations) same double-stranded DNA of recovery method (dsDNA) library.
Agarose gel electrophoresis is observed PCR result
The sepharose of preparation 2%: accurately take 2g electrophoresis level agarose, add 100ml 1XTAE electrophoretic buffer, in microwave oven, be heated to dissolve, when gel is cooled to 55 ℃ of left and right, add ethidium bromide (final concentration is 0.5 μ g/mL) to rotate and shake up gently, pour glued membrane into, insert suitable comb, use after allowing gelating soln condense.
PCR product electrophoresis: gel is placed in to electrophoresis chamber, get 3 μ LPCR products and add 1 μ l 6X loading buffer (0.25% tetrabromophenol sulfonphthalein, 0.25% dimethylbenzene cyanogen, 30% aqueous glycerin solution), loading after mixing, separately get 5 μ LDL Marker, add respectively in sepharose hole, in 1XTAE electrophoretic buffer, 80V electrophoresis 15-20min observes electrophoresis result on gel imaging instrument.
Embodiment bis-, SELEX screening
1. albumen is coated
With the carbonate buffer solution of pH9.60.05mol/L, PP65 albumen is diluted to desired concn, adds 100 μ l in each hole of each SELEX96 orifice plate (polystyrene board), establish blank hole and anti-sieve control wells simultaneously, 4 ℃ are spent the night.Next day, discards solution in hole, with lavation buffer solution PBST, washes three times.
2. sealing
3% BSA (calf serum), 37 ℃ of sealings are spent the night for 1 hour or 4 ℃.
The combination in 3.ssDNA library
The ssDNA library 100 μ l that add SELEX binding buffer to dilute, first hatch with blank hole (or anti-sieve contrasts empty) 37 ℃, anti-sieve is removed the ssDNA with target protein non-specific binding, then transfer in the coated hole of PP65 albumen 37 ℃ and hatch, with SELEX washing buffer washing 5 times.
4. wash-out
Add SELEX eluting buffer, in 80 ℃ of water-bath effect 10min, under wash-out with protein bound ssDNA.
5. the ssDNA of phenol-chloroform extracting, the combination of ethanol deposition and purification
Toward filling, in the 1.5mL Ep pipe of DNA solution to be purified, add isopyknic phenol: chloroform: primary isoamyl alcohol (25:24:1 volume ratio), on spiral mixer oscillator, vibration mixes, the centrifugal 15s of room temperature 12000rpm.With liquid-transfering gun by the upper strata of containing DNA (water) careful new Ep pipe of immigration, toward the sodium acetate (NaAc) and 2~2.5 times of dehydrated alcohols that volume is ice-cold that add the 3mol/L pH5.2 of 0.1 times of volume in ssDNA solution, on spiral mixer oscillator, vibration mixes and is placed in-20 ℃ of 30min, then the centrifugal 5min of 12000rpm, abandon supernatant, 70% ethanol that adds 1mL precooling, put upside down centrifuge tube for several times, the centrifugal 5min of 12000rpm, abandon supernatant, after drying precipitation, be dissolved in 20 μ LTE damping fluid (PH8.0) or ddH20,4 ℃ of preservations.
SsDNA library after being screened by PCR and asymmetric PCR, then carries out electrophoresis detection.Finally carry out altogether 8 take turns screening reach capacity, obtain specificity the highest, the ssDNA library that avidity is the strongest.
Embodiment tri-, Cloning and sequencing
1. reclaiming product connects
The saturated library of screening is connected to pMD18-T Simple Vector(TaKaRa company).
Amplification obtains biotin labeled ssDNA library through asymmetric PCR by the 8th, to take turns the ssDNA library obtaining, by cytomegalovirus PP65 for albumen carbonate (PH9.6) damping fluid be diluted to 10 μ g/ml, get the coated elisa plate of 100 μ l, 4 ℃ are spent the night, PBST (PBS+Tween) washing 4 times, 3min/ time; 3%BSA37 ℃ is sealed 1 hour, PBST washing 4 times, 3min/ time; With the 8th of SELEX binding buffer dilution, take turns biotin labeled ssDNA0.05 μ g/ hole, 37 ℃ of incubation 60min, PBST washing 6 times, 3min/ time; 37 ℃ of the horseradish peroxidases of the marked by streptavidin of dilution in 1: 1000 are hatched 30min, PBST washing 6 times, 3min/ time; Add 37 ℃ of colour developing 15min of tetramethyl benzidine (tetramethylbenzidine, TMB) nitrite ion; 2mol/L vitriol oil termination reaction, microplate reader is measured A value in 450nm place.A value is greater than 0.1, reclaims product, and screening product is connected to pMD18-T simple vector (TaKaRa company).With reference to the pMD18-T Simple Vector of the TaKaRa company description of product, the goal gene PCR product after purifying is connected with cloning vector pMD18-TSimple Vector, 16 ℃ of connections are spent the night.
2. connect the conversion of product
A: by being connected in the EP pipe that product 20 μ L add the E.coli DH5a competent cell that contains 100ul of goal gene fragment and pMD18-T Simple Vector, ice bath 30min.
B: put into 42 ℃ of water-bath heat-shocked 1min, will manage fast and take out ice bath 2min.
C: every pipe adds SOC nutrient solution 600 μ l, 37 ℃ of shaking tables, 150rpm, cultivates 1h, makes the antibiotics resistance marker gene of bacteria resuscitation expression plasmid coding.
D: the competent cell that proper volume has been transformed is coated on the LB flat board that contains penbritin 100 μ g/ml, and flat board is placed in to room temperature until liquid is absorbed.
E: be inverted flat board, in 37 ℃ of constant temperature culture, occur bacterium colony after 12~16h, the several bacterium colony PCR of random picking identify.
F: random 110 mono-clonals of picking, add in the 1.5ml EP pipe that fills 600 μ L LB liquid nutrient mediums (containing penbritin 100 μ g/ml) 37 ℃ of shaking tables, 200rpm, overnight incubation.Add 600 μ L(equivalent next day) 80% autoclaving glycerine, sealing orifice, preserves bacterial classification in-70 ℃.
3. the extraction of recombinant plasmid
Get 50 μ L mono-clonal bacterium liquid and be inoculated in 5ml containing the LB substratum of penbritin 100 μ g/ml, 37 ℃ of shaking tables, 250rpm, overnight incubation.With plasmid extraction test kit, extract recombinant plasmid.
4.PCR identifies
The extraction plasmid of take is template, adds SELEX primer I and primer I I to carry out pcr amplification reaction, and product electrophoresis is determined positive colony, and send the order-checking of order-checking company.
The sequence of human cytomegalic inclusion disease virus PP65 antigen aptamer:
A4
GGGAGCTCAGAATAAACGCTCAAGGCATGGTCCTCGATCGTATGGCTTTGCGGTCGTGTTCGACATGAGGCCCGGATC
A5
GGGAGCTCAGAATAAACGCTCAATATCCCTATTCCGCTCCATGTTGCGTACCCGTGCCTTCGACATGAGGCCCGGATC
A6
GGGAGCTCAGAATAAACGCTCAACGGATTAGTCAATAGACTGGTGGCTTTGTGTGGTGTTCGACATGAGGCCCGGATC
A7
GGGAGCTCAGAATAAACGCTCAATATCCCTATTCCGCTCCATGCTGCGTACCCGTGCCTTCGACATGAGGCCCGGATC
A10
GGGAGCTCAGAATAAACGCTCAATGTGTTCATTTTTGGGGCTTGCGGGTGGTTCGCTGTTCGACATGAGGCCCGGATC
A19
GGGAGCTCAGAATAAACGCTCAACGTCCCTCTCGTGTTGCTGCTGCTTTTTCCTGTGGTTCGACATGAGGCCCGGATC
5. fit affinity detects
The single clone who selects is obtained to ssDNA after SELEX primer I and the amplification of primer III asymmetric PCR, and by this ssDNA and the protein binding being coated with, enzyme-linked method is measured its affinity.By the coated hole of every hole 1 μ g ssDNA and 2 μ g albumen in 100 μ Lselex binding buffer 37 ℃ hatch 40 min; Selex washing buffer washing 5 times,, add marked by streptavidin horseradish peroxidase 100 μ L, hatch 30min for 37 ℃; Lavation buffer solution washing 5 times, then every hole adds each 50 μ L of substrate nitrite ion A, B, 37 ℃ of colour developing 15min; The 2mol/L vitriol oil 50 μ L termination reactions, microplate reader is measured absorbancy (A) value in 450nm place.Record fit affinity as follows:
The affinity distribution plan of (referring to Fig. 1) human cytomegalic inclusion disease virus PP65 antigen aptamer and target material
Numbering OD value Numbering OD value
A4 2.726 A10 1.271
A5 1.054 A19 1.137
A6 1.522 NC 0.067
A7 1.629 ? ?
The negative contrast of note: NC.

Claims (2)

1. there is a specific aptamer with human cytomegalic inclusion disease virus PP65 antigen, it is characterized in that: one of sequence that it is SEQ ID No.1~SEQ ID No.6.
2. a kind of according to claim 1 have specific aptamer with human cytomegalic inclusion disease virus PP65 antigen, it is characterized in that the secondary conformation of SEQ ID No.1~SEQ ID No.6 respectively is:
CN201310549433.8A 2013-11-07 2013-11-07 A kind of have specific aptamer with human cytomegalic inclusion disease virus PP65 antigen Active CN104046630B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310549433.8A CN104046630B (en) 2013-11-07 2013-11-07 A kind of have specific aptamer with human cytomegalic inclusion disease virus PP65 antigen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310549433.8A CN104046630B (en) 2013-11-07 2013-11-07 A kind of have specific aptamer with human cytomegalic inclusion disease virus PP65 antigen

Publications (2)

Publication Number Publication Date
CN104046630A true CN104046630A (en) 2014-09-17
CN104046630B CN104046630B (en) 2016-06-08

Family

ID=51500028

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310549433.8A Active CN104046630B (en) 2013-11-07 2013-11-07 A kind of have specific aptamer with human cytomegalic inclusion disease virus PP65 antigen

Country Status (1)

Country Link
CN (1) CN104046630B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104946655A (en) * 2015-07-01 2015-09-30 上海市肺科医院 DNA aptamer of mycobacterium tuberculosis standard strain H37Rv and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102242123A (en) * 2011-06-09 2011-11-16 中国人民解放军第三军医大学第一附属医院 Cytomegalovirus antibody aptamer specific to cytomegalovirus, and biochip formed by same
CN102312019A (en) * 2011-06-09 2012-01-11 中国人民解放军第三军医大学第一附属医院 Biological chip for rapidly detecting pre-pregnant intrauterine toxoplasma gondii and cytomegalovirus infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102242123A (en) * 2011-06-09 2011-11-16 中国人民解放军第三军医大学第一附属医院 Cytomegalovirus antibody aptamer specific to cytomegalovirus, and biochip formed by same
CN102312019A (en) * 2011-06-09 2012-01-11 中国人民解放军第三军医大学第一附属医院 Biological chip for rapidly detecting pre-pregnant intrauterine toxoplasma gondii and cytomegalovirus infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
夏宇 等: "人巨细胞病毒实验室诊断进展", 《国际检验医学杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104946655A (en) * 2015-07-01 2015-09-30 上海市肺科医院 DNA aptamer of mycobacterium tuberculosis standard strain H37Rv and preparation method thereof

Also Published As

Publication number Publication date
CN104046630B (en) 2016-06-08

Similar Documents

Publication Publication Date Title
CN111693712B (en) Method for detecting SARS-CoV-2N protein of new coronavirus by using nucleic acid aptamer
CN103543275B (en) Method for rapidly detecting PP65 based on magnetic bead
CN110117595B (en) Aptamer specifically binding to PDL1 and application thereof
CN108559792B (en) Real-time fluorescent quantitative PCR (polymerase chain reaction) primer, kit and method for detecting titer of lentivirus
CN111040031B (en) ScFv antibody for resisting African swine fever virus and preparation method thereof
CN111560069B (en) Single-chain antibody for resisting African swine fever virus and preparation method and application thereof
CN102822353A (en) Method of determining and confirming the presence of an HPV in a sample
RU2014122607A (en) METHODS FOR DETERMINING A PATIENT'S SUSCEPTIBILITY TO IN-HOSPITAL INFECTION AND FORMING A FORECAST OF SEPTIC SYNDROME DEVELOPMENT
Colletti et al. Human cytomegalovirus UL84 interacts with an RNA stem-loop sequence found within the RNA/DNA hybrid region of ori Lyt
CN104020291B (en) A kind of HPV nucleic acid detection kit based on enzyme-linked immuno assay and application thereof
WO2012103337A2 (en) Assays and methods to sequence microbes directly from immune complexes
CN113307877B (en) Preparation and application of nano antibody capable of simultaneously recognizing fenitrothion and methyl parathion
CN103232998A (en) Kit for separating RNA (ribonucleic acid) bound in RNA binding protein
CN103558380B (en) Method for quickly detecting PP65 based on biochip
CN104046630A (en) Aptamer having specificity with human cytomegalovirus PP65 antigen
JP2013533865A5 (en)
CN108220391A (en) A kind of transcription factor co-immunoprecipitation(ChIP)Agent prescription
Li et al. Recent developments in affinity-based selection of aptamers for binding disease-related protein targets
CN102234648A (en) Toxoplasma gondii antibody aptamer with specificity to toxoplasma gondii bacteria and constructed biochip
CN104988155A (en) Aptamer capable of being combined with human nasopharyngeal cancer LMP2A and biochip composed of same
CN102312019B (en) Biological chip for rapidly detecting pre-pregnant intrauterine toxoplasma gondii and cytomegalovirus infection
CN102242123B (en) Cytomegalovirus antibody aptamer specific to cytomegalovirus, and biochip formed by same
CN114774337A (en) HCoV-229E virus detection system based on engineering escherichia coli
CN114774425A (en) MERS-CoV virus detection system based on engineering escherichia coli
CN102382813A (en) Systematic evolution of ligands by exponential enrichment (SELEX) technical method aiming at electrophoresis gel retardation of liquid-phase non-purification composite targets

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant